- Home
- MCRB vs SCLX Comparison
MCRB vs SCLX Comparison
Compare MCRB & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- SCLX
- Stock Information
- Founded
- MCRB 2010
- SCLX 2011
- Country
- MCRB United States
- SCLX United States
- Employees
- MCRB N/A
- SCLX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- SCLX Health Care
- Exchange
- MCRB Nasdaq
- SCLX Nasdaq
- Market Cap
- MCRB N/A
- SCLX 130.1M
- IPO Year
- MCRB 2015
- SCLX N/A
- Fundamental
- Price
- MCRB $0.59
- SCLX $0.68
- Analyst Decision
- MCRB Buy
- SCLX Strong Buy
- Analyst Count
- MCRB 4
- SCLX 3
- Target Price
- MCRB $5.63
- SCLX $11.33
- AVG Volume (30 Days)
- MCRB 2.2M
- SCLX 184.3K
- Earning Date
- MCRB 11-13-2024
- SCLX 11-26-2024
- Dividend Yield
- MCRB N/A
- SCLX N/A
- EPS Growth
- MCRB N/A
- SCLX N/A
- EPS
- MCRB N/A
- SCLX N/A
- Revenue
- MCRB $126,325,000.00
- SCLX $50,833,000.00
- Revenue This Year
- MCRB N/A
- SCLX $32.77
- Revenue Next Year
- MCRB $215.76
- SCLX $50.71
- P/E Ratio
- MCRB N/A
- SCLX N/A
- Revenue Growth
- MCRB N/A
- SCLX 9.41
- 52 Week Low
- MCRB $0.54
- SCLX $0.63
- 52 Week High
- MCRB $2.05
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- MCRB 28.31
- SCLX 32.00
- Support Level
- MCRB $0.68
- SCLX $0.73
- Resistance Level
- MCRB $0.76
- SCLX $1.14
- Average True Range (ATR)
- MCRB 0.06
- SCLX 0.10
- MACD
- MCRB -0.01
- SCLX -0.03
- Stochastic Oscillator
- MCRB 4.51
- SCLX 9.80
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.